Personalis (NASDAQ:PSNL) Trading 14.8% Higher – Time to Buy?

Personalis, Inc. (NASDAQ:PSNL) rose 14.8% during mid-day trading on Thursday . The company traded as high as $11.00 and last traded at $11.0750. Approximately 413,681 shares changed hands during trading, a decline of 69% from the average daily volume of 1,327,764 shares. The stock had previously closed at $9.65.

Wall Street Analysts Forecast Growth

Several equities research analysts have recently issued reports on the stock. HC Wainwright increased their price objective on shares of Personalis from $8.50 to $10.00 and gave the stock a “buy” rating in a research report on Thursday, November 6th. Weiss Ratings restated a “sell (d-)” rating on shares of Personalis in a report on Wednesday, October 8th. BTIG Research reiterated a “buy” rating and set a $12.00 price objective on shares of Personalis in a report on Friday, January 9th. Wall Street Zen lowered Personalis from a “hold” rating to a “sell” rating in a research report on Saturday, January 3rd. Finally, Morgan Stanley upped their price target on Personalis from $9.00 to $11.00 and gave the stock an “equal weight” rating in a research report on Monday, December 1st. Six analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and a consensus target price of $10.57.

Personalis Trading Up 18.5%

The firm has a market capitalization of $1.02 billion, a price-to-earnings ratio of -13.01 and a beta of 1.96. The company’s 50 day moving average is $8.93 and its 200-day moving average is $7.41.

Personalis (NASDAQ:PSNL) last released its quarterly earnings data on Tuesday, November 4th. The company reported ($0.24) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.28) by $0.04. Personalis had a negative return on equity of 38.25% and a negative net margin of 106.92%.The firm had revenue of $14.50 million for the quarter, compared to analyst estimates of $13.31 million. Research analysts expect that Personalis, Inc. will post -1.4 EPS for the current year.

Insider Buying and Selling at Personalis

In other news, CFO Aaron Tachibana sold 103,668 shares of the stock in a transaction dated Tuesday, November 25th. The shares were sold at an average price of $10.78, for a total value of $1,117,541.04. Following the transaction, the chief financial officer directly owned 164,458 shares of the company’s stock, valued at $1,772,857.24. This represents a 38.66% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, CEO Christopher M. Hall sold 29,612 shares of the business’s stock in a transaction dated Monday, November 3rd. The shares were sold at an average price of $8.99, for a total transaction of $266,211.88. Following the completion of the sale, the chief executive officer directly owned 148,486 shares of the company’s stock, valued at approximately $1,334,889.14. The trade was a 16.63% decrease in their position. The SEC filing for this sale provides additional information. 3.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Personalis

Large investors have recently added to or reduced their stakes in the stock. Legal & General Group Plc bought a new position in Personalis during the 2nd quarter worth $30,000. Ameritas Investment Partners Inc. bought a new position in shares of Personalis in the second quarter worth $34,000. BNP Paribas Financial Markets increased its position in shares of Personalis by 406.4% in the second quarter. BNP Paribas Financial Markets now owns 6,451 shares of the company’s stock worth $42,000 after purchasing an additional 5,177 shares during the period. Focus Partners Wealth acquired a new position in Personalis in the first quarter valued at about $47,000. Finally, Farther Finance Advisors LLC bought a new stake in Personalis during the third quarter worth about $66,000. Institutional investors and hedge funds own 61.91% of the company’s stock.

About Personalis

Personalis, Inc (NASDAQ: PSNL) is a clinical‐stage genomics company that develops and markets advanced next‐generation sequencing (NGS) services and assays designed to accelerate precision medicine. The Company’s core offering is the ImmunoID NeXT™ Platform, which combines comprehensive tumor profiling—including whole exome, transcriptome, and T‐cell receptor sequencing—with proprietary bioinformatics to identify biomarkers and guide immuno‐oncology research. Personalis serves biopharmaceutical companies, academic institutions, and clinical research organizations seeking in‐depth insights into cancer, autoimmune diseases and other complex conditions.

In addition to its flagship ImmunoID NeXT™ Platform, Personalis offers a suite of customizable sequencing assays for biomarker discovery, clinical trial support and companion diagnostic development.